Dialysis Equipment in Minnesota

Medica USA Inc. is a vertically integrated biomedical manufacturer and technology developer based in Eden Prairie, Minnesota, with parent company operations in Mirandola, Italy since 1985. The company specializes in blood purification devices and systems, including dialysis, continuous renal replacement therapy (CRRT), and apheresis equipment and disposables. Core competencies span electromedical device design, hollow-fiber membrane technology, and disposable medical device manufacturing. Beyond renal care, Medica serves cardiology, surgical oncology, organ transplantation, urology, and gastroenterology diagnostic markets. The company operates three integrated business units: Medical (blood purification products and devices), Water Purification (industrial and hospital water treatment systems using proprietary membrane technology), and Turnkey Solutions (complete system integration and industrial automation for the biomedical sector). Medica maintains in-house R&D, manufacturing, quality assurance, regulatory affairs, sales, and after-sales service. The company holds an extensive portfolio of proprietary patents and is ISO-certified for medical device production. All products are manufactured under strict compliance with regulatory requirements for US, European, and international markets.

Mozarc Medical is a healthcare technology company dedicated to improving kidney health, launched in April 2023 as a spinoff leveraging expertise from Medtronic's former Renal Care Solutions business. The company offers a comprehensive portfolio of kidney health solutions including hemodialysis catheters, peritoneal dialysis catheters, safety fistula cannulas, and specialized pediatric dialysis systems. Mozarc Medical emphasizes reducing complications and enhancing patient access to care, particularly for in-home dialysis environments. The company provides clinical support, education, and training resources to healthcare providers and patients, focusing on holistic kidney care solutions spanning vascular access through treatment delivery. Led by CEO Ven Manda with a global workforce, Mozarc Medical serves nephrology practices, dialysis centers, and home care programs treating chronic kidney disease, end-stage renal disease, and acute kidney injury patients.

Nuwellis, Inc. is a commercial-stage medical device manufacturer specializing in ultrafiltration therapy systems for fluid management in cardiorenal patients. Founded in 1999 and headquartered in Eden Prairie, Minnesota, the company develops and markets the Aquadex FlexFlow System and Aquadex SmartFlow System—precision ultrafiltration devices designed to remove excess fluid in patients with heart failure, acute kidney injury, chronic kidney disease, and cardiorenal syndrome when diuretics prove inadequate. The systems deliver predictable, isotonic fluid removal while protecting organ function and reducing hospitalizations and readmissions. Nuwellis supports critical care, pediatric, nephrology, cardiology, and outpatient settings with comprehensive clinical evidence from 65+ peer-reviewed studies spanning 20+ years. The company provides integrated cardiorenal management solutions, clinical training, reimbursement support, and dedicated customer service to healthcare providers globally, addressing both acute perioperative fluid management and chronic disease management.

Phraxis is a medical device company specializing in innovative endovascular solutions for hemodialysis access. The company's flagship product, EndoForce™ Connector, is an FDA-approved device designed to create arteriovenous grafts (AVG) for hemodialysis patients using a minimally invasive, endovascular approach. EndoForce™ eliminates the need for surgical dissection required in traditional sutured anastomosis techniques and enables precise, coaxial vessel-to-graft alignment through standard transcatheter methods. The device features a patented design incorporating a flexible nitinol segment for versatile implantation angles and a rigid segment with nitinol barbs for secure attachment. In pivotal clinical trials, EndoForce™ demonstrated a 92% cumulative patency rate, exceeding the 80% rate associated with conventional suture anastomosis, thereby extending graft longevity and reducing complications. The company was founded by Dr. Alex Yevzlin, an interventional nephrologist whose clinical expertise in dialysis access informed the product's development. Phraxis targets nephrology and vascular surgery markets, addressing critical clinical challenges in hemodialysis access creation with a precision-engineered, reproducible endovascular solution.

Di-Chem, Inc. is a family-owned medical device manufacturing and contract services company based in Champlin, Minnesota, operating since 1982. The company specializes in the production of dialysate additives and related consumables for the healthcare and life sciences industries. Di-Chem provides contract manufacturing, contract packaging, custom powder and liquid filling, and private label manufacturing services. The company serves dialysis equipment manufacturers and healthcare providers by delivering high-quality, cost-effective solutions tailored to evolving customer requirements. With a focus on adaptability and quality, Di-Chem supports the broader medical device supply chain through specialized formulations and manufacturing capabilities.